GTC Biotherapeutics (fka GTCB)

[Pre_Clinical]

>>>>>>>>>
LOL this excedes ridiculous. Give him one more aliais Mabad. The fact we have people on this site that were taken in by this guy is embarrasing. Low point in his comments was his attack on Atryn's use in DIC by dismissing the results as pertaining to a "subset" of patients. Yeah they were a subset alright, those who received AT3 without Heparin. This group was identified by careful analysis and showed a 14% increase in long term survival. This is hugely significant and unless shown to be in error by studies will indeed turn Atryn into a blockbuster drug.
<<<<<<<

I expressed concern about the risk involved in starting a clinical trial in sepsis (the graveyard of many a program) based on a subgroup analysis of a previous clinical trial, and you're the one laughing? You obviously haven't been in this game very long. I also stated that the sepsis program "is tantalizing" but that "I'm not pinning my hopes on it".

It's amazing how there appears to be a zero tolerance policy for any critical analysis of this company's programs and/or technology. Talk about group-think. It's like the DNDN board.

As I stated, I believe that the future of this company involves mAbs and FOB's. That's all. And it's undervalued at that. It's called objectivity. Look it up. I would encourage you to try and be a little more open-minded.